Pancreatic Cancer Research

ResearcherJichi Medical UniversityActive in the last 2 years

Toshiki Rikiyama

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5112654985. Sources: OpenAlex.

Their work

Papers
13 (first author 1, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
72
Papers, trials and grants by year

2011: 3 papers · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 2 papers · 2020: none · 2021: 1 paper · 2022: 3 papers · 2023: 1 paper · 2024: none · 2025: 2 papers · 2026: 1 paper

Papers 13

  1. DNA Hypomethylation in Pancreatic Cancer Tissues Before Treatment, Defined by KRAS -mutated Circulating Tumor DNA, is Associated With Poor Prognosis. Last author DOI 10.1097/mpa.0000000000002650↗
  2. Patients With Pancreatic Cancer With Synchronous Liver Oligometastasis Show a Significant Long-Term Survival Benefit From Resection Under Specific Conditions: … Co-author DOI 10.1002/jhbp.12181↗
  3. Three Molecular Developmental Pathways of Remnant Pancreatic Cancer After Resection: A Nationwide Project Study of Japan Pancreas Society. Co-author DOI 10.1097/sla.0000000000006444↗
  4. Circulating tumor DNA in molecular assessment feasibly predicts early progression of pancreatic cancer that cannot be identified via initial imaging. Last author DOI 10.1038/s41598-023-31051-7↗
  5. Outcomes of lung metastasis from pancreatic cancer: A nationwide multicenter analysis. Co-author DOI 10.1002/jhbp.1127↗
  6. Liquid biopsy leads to a paradigm shift in the treatment of pancreatic cancer. Last author DOI 10.3748/wjg.v28.i46.6478↗
  7. Genome‑wide DNA hypomethylation drives a more invasive pancreatic cancer phenotype and has predictive occult distant metastasis and prognosis potential. Last author DOI 10.3892/ijo.2022.5351↗
  8. Optimal value of CA19-9 determined by KRAS-mutated circulating tumor DNA contributes to the prediction of prognosis in pancreatic cancer patients. Last author DOI 10.1038/s41598-021-00060-9↗
  9. A lack of postoperative complications after pancreatectomy contributes to the long-term survival of patients with pancreatic cancer. Last author DOI 10.1016/j.pan.2019.06.012↗
  10. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer. Last author DOI 10.1371/journal.pone.0227366↗
  11. Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study. Co-author DOI 10.1007/s10147-011-0220-8↗
  12. Severe cholestatic liver failure associated with gemcitabine adjuvant monotherapy for pancreatic cancer. Co-author DOI 10.1007/s12328-011-0257-2↗
  13. Retrospective evaluation of the influence of postoperative tumor marker status on survival and patterns of recurrence after surgery for pancreatic cancer based… First author DOI 10.1245/s10434-010-1311-x↗

Closest collaborators

The 25 strongest of 72 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Fumiaki Watanabe · 7 shared papers, 2019–2026 · strength 1.12
  2. Yuhei Endo · 6 shared papers, 2019–2026 · strength 0.90
  3. Shugo Mizuno · 3 shared papers, 2022–2025 · strength 0.43
  4. Masaji Tani · 3 shared papers, 2022–2025 · strength 0.43
  5. Satoshi Hirano · 3 shared papers, 2022–2025 · strength 0.43
  6. Itaru Endo · 3 shared papers, 2022–2025 · strength 0.43
  7. Kenichi Hakamada · 2 shared papers, 2025 · strength 0.32
  8. Sohei Satoi · 2 shared papers, 2025 · strength 0.32
  9. Shuji Suzuki · 2 shared papers, 2025 · strength 0.32
  10. Masayuki Ohtsuka · 2 shared papers, 2025 · strength 0.32
  11. Koetsu Inoue · 1 shared paper, 2026 · strength 0.28
  12. Hiroki Yamaue · 2 shared papers, 2022–2025 · strength 0.27
  13. Michiaki Unno · 4 shared papers, 2011–2025 · strength 0.24
  14. Takeshi Sudo · 1 shared paper, 2025 · strength 0.16
  15. Hiroaki Nagano · 1 shared paper, 2025 · strength 0.16
  16. Dongha Lee · 1 shared paper, 2025 · strength 0.16
  17. Masafumi Imamura · 1 shared paper, 2025 · strength 0.16
  18. Masaaki Hidaka · 1 shared paper, 2025 · strength 0.16
  19. Teijiro Hirashita · 1 shared paper, 2025 · strength 0.16
  20. Akihiko Horiguchi · 1 shared paper, 2025 · strength 0.16
  21. Naoto Gotohda · 1 shared paper, 2025 · strength 0.16
  22. Shigeru Marubashi · 1 shared paper, 2025 · strength 0.16
  23. Kohei Nakata · 1 shared paper, 2025 · strength 0.16
  24. Masafumi Nakamura · 1 shared paper, 2025 · strength 0.16
  25. Masamichi Mizuma · 1 shared paper, 2025 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.